Payment overview · 2025
General Payments
$972.17
44 reported records · 17 companies
Healthcare provider profile · identity verified
Regina Davis, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALPHARETTA, GA · NPI 1386126290
Verified facts
What the public records show
CMS Open Payments records show Regina Davis, NP received $972.17 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.29 | 17.1% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $99.07 | 10.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.48 | 9.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.58 | 9.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.78 | 8.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.98 | 7.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.76 | 6.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.32 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.78 | 5.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.90 | 4.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.12 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.49 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.18 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.77 | 2.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.83 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.56 | 2.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $972.17 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $109.07 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $99.07 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.98 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.76 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.74 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.16 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.77 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.78 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.78 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.90 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.06 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 286 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 231 | 70 |
| Metformin Hcl | Metformin Hcl | 184 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 58 |
| Omeprazole | Omeprazole | 157 | 46 |
| Simvastatin | Simvastatin | 157 | 44 |
| Losartan Potassium | Losartan Potassium | 146 | 49 |
| Gabapentin | Gabapentin | 144 | 50 |
| Lisinopril | Lisinopril | 138 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 27 |
| Famotidine | Famotidine | 77 | 28 |
| Carvedilol | Carvedilol | 76 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 24 |
| Ezetimibe | Ezetimibe | 71 | 18 |
| Trazodone Hcl | Trazodone Hcl | 70 | 20 |
| Fenofibrate | Fenofibrate | 69 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 49 | 14 |
| Potassium Chloride | Potassium Chloride | 49 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 14 |
| Ozempic | Semaglutide | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 18 |
| Allopurinol | Allopurinol | 42 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 17 |
| Topiramate | Topiramate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 13 |
| Atenolol | Atenolol | 34 | 11 |
| Furosemide | Furosemide | 30 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $972.17 · 44 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COBENFY, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error